{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T04:32:45Z","timestamp":1775190765062,"version":"3.50.1"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2001,1,1]],"date-time":"2001-01-01T00:00:00Z","timestamp":978307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2001,1]]},"DOI":"10.1016\/s0304-3835(00)00605-4","type":"journal-article","created":{"date-parts":[[2002,7,25]],"date-time":"2002-07-25T13:29:51Z","timestamp":1027603791000},"page":"39-48","source":"Crossref","is-referenced-by-count":26,"title":["Cyclophosphamide and 5-fluorouracil act synergistically in ovarian clear cell adenocarcinoma cells"],"prefix":"10.1016","volume":"162","author":[{"given":"Ichiro","family":"Ohta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itsuo","family":"Gorai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasunori","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian Hua","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi","family":"Kawata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiki","family":"Hirahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoich","family":"Shirotake","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/S0304-3835(00)00605-4_BIB1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1006\/gyno.1995.1097","article-title":"Establishment and characterization of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with different properties","volume":"57","author":"Gorai","year":"1995","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB2","first-page":"954","article-title":"Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma","volume":"80","author":"Fanning","year":"1992","journal-title":"Obstet Gynecol."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB4","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/cncr.2820710422","article-title":"Second-line chemotherapy for recurrent carcinoma of the ovary","volume":"71","author":"Thigpen","year":"1993","journal-title":"Cancer"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0140-6736(96)06071-0","article-title":"Epithelial ovarian carcinoma","volume":"349","author":"Kristensen","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB6","doi-asserted-by":"crossref","first-page":"690","DOI":"10.2165\/00003495-199244050-00002","article-title":"Prediction of response to drug therapy of cancer \u2013 a review of in vitro assays","volume":"44","author":"Bellamy","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB7","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1056\/NEJM199311183292108","article-title":"Cancer of the ovary","volume":"329","author":"Cannistra","year":"1993","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB8","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/bjc.1997.471","article-title":"Complexity of expression of the intermediate filaments of six new human ovarian carcinoma cell lines: new expression of cytokeratin 20","volume":"76","author":"Yanagibashi","year":"1997","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB9","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB10","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/j.1349-7006.1995.tb03316.x","article-title":"Phase I study of paclitaxel by three-hour infusion: hypotension just after infusion is one of the major dose-limiting toxicities","volume":"86","author":"Tamura","year":"1995","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB11","first-page":"1997","article-title":"Phase I clinical trial of RP56976 (docetaxel) a new anticancer drug","volume":"21","author":"Taguchi","year":"1994","journal-title":"Gan To Kagaku Ryoho"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0163-7258(80)90058-3","article-title":"In vitro systems for evaluation of combination chemotherapy","volume":"8","author":"Momparler","year":"1980","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB13","series-title":"Human Tumor Cloning","first-page":"451","article-title":"A new bioassay for in vitro drug stability","author":"Hildebrand-Zanki","year":"1984"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1006\/gyno.1997.4637","article-title":"Apoptosis as a measure of chemosensitivity to cisplatin and taxol therapy in ovarian cancer cell lines","volume":"65","author":"Gibb","year":"1997","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB15","first-page":"2785","article-title":"The effect of phenobarbital on cyclophosphamide antitumor activity","volume":"36","author":"Alberts","year":"1976","journal-title":"Cancer Res."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB16","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/BF00262767","article-title":"Cell killing action of cell cycle phase-non-specific antitumor agents is dependent on concentration-time product","volume":"21","author":"Ozawa","year":"1988","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB17","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1002\/1097-0142(19921115)70:10<2540::AID-CNCR2820701024>3.0.CO;2-2","article-title":"In vitro measurement of chemosensitivity of human small cell lung and gastric cancer cell lines toward cell cycle phase-nonspecific agents under the clinically equivalent area under the curve","volume":"70","author":"Mitsuhashi","year":"1992","journal-title":"Cancer"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB18","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/gyno.1995.1205","article-title":"Cell biological markers of drug resistance in ovarian carcinoma","volume":"58","author":"Van der Zee","year":"1995","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB19","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0305-7372(90)90081-P","article-title":"The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin","volume":"17","author":"Meijer","year":"1990","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB20","first-page":"304","article-title":"Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung cancer cell line","volume":"50","author":"De Jong","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5","article-title":"Molecular effects of paclitaxel: myths and reality (a critical review)","volume":"83","author":"Blagosklonny","year":"1999","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB22","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1038\/bjc.1993.488","article-title":"Cytotoxic studies of paclitaxel (Taxol\u00ae) in human tumor cell lines","volume":"68","author":"Liebmann","year":"1993","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB23","first-page":"5276","article-title":"Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma","volume":"55","author":"Andreotti","year":"1995","journal-title":"Cancer Res."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/sj.bjc.6690046","article-title":"Additive and supraadditive cytotoxicity of cisplatin-taxane combinations in ovarian carcinoma cell lines","volume":"79","author":"Engblom","year":"1999","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB25","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.1994.55","article-title":"Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro","volume":"69","author":"Jekunen","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB26","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/0959-8049(94)00440-G","article-title":"Schedule-dependent antagonism of paclitaxel and cisplatin in human gastric and ovarian carcinoma cell lines in vitro","author":"Vanhoefer","year":"1995","journal-title":"Eur. J. Cancer, 31A"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB27","first-page":"2425","article-title":"Cisplatin inhibits pacitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for the failure of combination therapy","volume":"59","author":"Judson","year":"1999","journal-title":"Cancer Res."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB28","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/0959-8049(95)00448-3","article-title":"Schedule-dependent interaction between paclitaxel and doxorubicin in human cancer cell lines in vitro","author":"Akutsu","year":"1995","journal-title":"Eur. J. Cancer, 31A"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB29","first-page":"2559","article-title":"Antagonistic interplay between antimitotic and G1-S arresting agents observed in experimental combination therapy","volume":"5","author":"Johnson","year":"1999","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB30","first-page":"1209","article-title":"Antineoplastic agents","author":"Calabresi","year":"1990"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB31","doi-asserted-by":"crossref","first-page":"8923","DOI":"10.1073\/pnas.83.23.8923","article-title":"Biochemical basis for cisplatin and 5-fluorouracil synergism in human ovarian carcinoma cells","volume":"83","author":"Scanlon","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/S0304-3835(00)00605-4_BIB32","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1093\/oxfordjournals.annonc.a057858","article-title":"Combination chemotherapy with cisplatin and 5-fluorouracil 5-day infusion in the therapy of advanced gastric cancer: a phase II trial","volume":"2","author":"Lacave","year":"1991","journal-title":"Ann. Oncol."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0002-9378(91)90075-3","article-title":"Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay","volume":"165","author":"Gerhardt","year":"1991","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/S0304-3835(00)00605-4_BIB34","first-page":"2620","article-title":"Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves","volume":"5","author":"Nishiyama","year":"1999","journal-title":"Clin. Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383500006054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383500006054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,24]],"date-time":"2019-04-24T17:29:35Z","timestamp":1556126975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383500006054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1]]}},"alternative-id":["S0304383500006054"],"URL":"https:\/\/doi.org\/10.1016\/s0304-3835(00)00605-4","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2001,1]]}}}